Amarantus Bioscience Holdings Inc (AMBS)

[Ann1]

Unpublished data in various orphan indications that the CEO could not discuss during his presentation.

Dr. Joe (from Amgen) talked about how the best way to get a drug to market quickly is through orphan indications – as what happened with Interferon that became worth billions!

In process of evaluating fastest path to market…works for me!

Generating sales/revenue within 12-18 month period.

AMBS owns the MANF technology. Bigger players are ALREADY looking at it.

Let's see if this works or disappears!

You have NO idea what I know or don't. Do not make assumptions. Your million dollar deals don't compare to my billion dollar deals. Nice try.